Novavax Inc (NAS:NVAX)
$ 17.851 2.821 (18.77%) Market Cap: 2.63 Bil Enterprise Value: 1.97 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Novavax Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 01:15AM GMT
Release Date Price: $12.41 (+1.22%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good afternoon. I'm Eric Joseph, senior biotech analyst at JPMorgan. Our next presenting company is Novavax. And I think I have the rare distinction of being probably one of the last few people to introduce CEO, Stan Erck, to bring us through -- to talk to us about the company. So we will be doing a Q&A after the presentation. Mic will be going around the floor, and you can also feel free to submit questions via the online digital conference book.

So with that, Stan.

Stanley Charles Erck
Novavax, Inc. - President, CEO & Director

Thank you, Eric. So the comment was, I think, related to the fact that after 42 wonderful years of never having a problem being in biotech, I have retired today. I announced my retirement today. And so I will be with the company for another year plus and working -- hoping to advise them on some of the collaborations that we've established on a global basis. But you're right, maybe the last introduction at a JPMorgan meeting in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot